Literature DB >> 16865778

Experimental study of osthole on treatment of hyperlipidemic and alcoholic fatty liver in animals.

Fang Song1, Mei-Lin Xie, Lu-Jia Zhu, Ke-Ping Zhang, Jie Xue, Zhen-Lun Gu.   

Abstract

AIM: To evaluate the effects of osthole on fatty liver, and investigate the possible mechanism.
METHODS: A quail model with hyperlipidemic fatty liver and rat model with alcoholic fatty liver were set up by feeding high fat diet and alcohol, respectively. These experimental animals were then treated with osthole 5-20 mg/kg for 6 wk, respectively. Whereafter, the lipid in serum and hepatic tissue, and coefficient of hepatic weight were measured.
RESULTS: After treatment with osthole the levels of serum total cholesterol (TC), triglyceride (TG), lower density lipoprotein-cholesterol (LDL-C), coefficient of hepatic weight, and the hepatic tissue contents of TC and TG were significantly decreased. The activity of superoxide dismutase (SOD) in liver was improved. In alcohol-induced fatty liver rats, the level of malondialdehyde (MDA) in liver was decreased. In high fat-induced fatty liver quails, glutathione peroxidase (GSH-PX) in liver was significantly improved. The histological evaluation of liver specimens demonstrated that the osthole dramatically decreased lipid accumulation.
CONCLUSION: These results suggested that osthole had therapeutic effects on both alcohol and high fat-induced fatty liver. The mechanism might be associated with its antioxidation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865778      PMCID: PMC4087747          DOI: 10.3748/wjg.v12.i27.4359

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

Review 1.  AGA technical review on nonalcoholic fatty liver disease.

Authors:  Arun J Sanyal
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

2.  Nonalcoholic fatty liver disease in developing countries.

Authors:  Hossein Bahrami
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

3.  Prevalence of fatty liver in a general population of Okinawa, Japan.

Authors:  H Nomura; S Kashiwagi; J Hayashi; W Kajiyama; S Tani; M Goto
Journal:  Jpn J Med       Date:  1988-05

4.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

Review 5.  Alcoholic liver disease.

Authors:  K Walsh; G Alexander
Journal:  Postgrad Med J       Date:  2000-05       Impact factor: 2.401

Review 6.  Non-alcoholic fatty liver disease.

Authors:  Paul Angulo; Keith D Lindor
Journal:  J Gastroenterol Hepatol       Date:  2002-02       Impact factor: 4.029

Review 7.  Nonalcoholic steatohepatitis.

Authors:  A E Reid
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

Review 8.  Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.

Authors:  Brent A Neuschwander-Tetri; Stephen H Caldwell
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

9.  Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis.

Authors:  A Nonomura; Y Mizukami; M Unoura; K Kobayashi; Y Takeda; R Takeda
Journal:  Gastroenterol Jpn       Date:  1992-08

10.  Clinical features and risk factors of patients with fatty liver in Guangzhou area.

Authors:  Qi-Kui Chen; Hai-Ying Chen; Kai-Hong Huang; Ying-Qiang Zhong; Ji-Ao Han; Zhao-Hua Zhu; Xiao-Dong Zhou
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

View more
  9 in total

1.  Lactobacillus rhamnosus CCFM1107 treatment ameliorates alcohol-induced liver injury in a mouse model of chronic alcohol feeding.

Authors:  Fengwei Tian; Feifei Chi; Gang Wang; Xiaoming Liu; Qiuxiang Zhang; Yongquan Chen; Hao Zhang; Wei Chen
Journal:  J Microbiol       Date:  2015-12-02       Impact factor: 3.422

2.  PPARα/γ antagonists reverse the ameliorative effects of osthole on hepatic lipid metabolism and inflammatory response in steatohepatitic rats.

Authors:  Xi Zhao; Feng Wang; Ruijun Zhou; Zengyan Zhu; Meilin Xie
Journal:  Inflammopharmacology       Date:  2017-02-25       Impact factor: 4.473

3.  Metabolic map of osthole and its effect on lipids.

Authors:  Qi Zhao; Xin-Mei Li; Hong-Ning Liu; Frank J Gonzalez; Fei Li
Journal:  Xenobiotica       Date:  2017-04-03       Impact factor: 1.908

4.  Application of Metabolomics in the Study of Natural Products.

Authors:  Qi Zhao; Jia-Le Zhang; Fei Li
Journal:  Nat Prod Bioprospect       Date:  2018-06-29

5.  Osthole: A Coumarin Derivative Assuage Thiram-Induced Tibial Dyschondroplasia by Regulating BMP-2 and RUNX-2 Expressions in Chickens.

Authors:  Muhammad Waqas; Yaping Wang; Aoyun Li; Hammad Qamar; Wangyuan Yao; Xiaole Tong; Jialu Zhang; Mudassar Iqbal; Khalid Mehmood; Jiakui Li
Journal:  Antioxidants (Basel)       Date:  2019-08-22

6.  Osthole Regulates Secretion of Pro-Inflammatory Cytokines and Expression of TLR2 and NF-κB in Normal Human Keratinocytes and Fibroblasts.

Authors:  Natalia Kordulewska; Justyna Topa; Anna Cieślińska; Beata Jarmołowska
Journal:  J Inflamm Res       Date:  2022-03-01

Review 7.  Osthole: A Review on Its Bioactivities, Pharmacological Properties, and Potential as Alternative Medicine.

Authors:  Zhong-Rong Zhang; Wing Nang Leung; Ho Yee Cheung; Chun Wai Chan
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-13       Impact factor: 2.629

8.  Osthole ameliorates hepatic fibrosis and inhibits hepatic stellate cell activation.

Authors:  Ya-Wei Liu; Yung-Tsung Chiu; Shu-Ling Fu; Yi-Tsau Huang
Journal:  J Biomed Sci       Date:  2015-08-01       Impact factor: 8.410

9.  Effects of Osthole on Inflammatory Gene Expression and Cytokine Secretion in Histamine-Induced Inflammation in the Caco-2 Cell Line.

Authors:  Natalia K Kordulewska; Justyna Topa; Dominika Rozmus; Beata Jarmołowska
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.